Achromatopsia
Achromatopsia is a rare inherited retinal disease that affects the cone photoreceptor cells of the retina, resulting in reduced or absent colour vision and significant sensitivity to light.
Understanding Achromatopsia
Achromatopsia is a rare inherited retinal disease caused by dysfunction of the cone photoreceptor cells in the retina, which are responsible for colour vision, sharp central vision and seeing in bright light.
People with achromatopsia typically experience complete or partial colour blindness, reduced visual acuity and sensitivity to light (photophobia). Symptoms are usually present from birth or early childhood and can make bright environments particularly challenging. The condition is sometimes referred to as total colour blindness or rod monochromacy.
Unlike many inherited retinal diseases, achromatopsia is generally non-progressive, with vision often remaining relatively stable throughout life, although some individuals may experience changes over time.
Although there is currently no cure, advances in genetic research are helping to improve understanding of achromatopsia and explore potential treatments. Retina International works with people affected by the condition, patient organisations, researchers and clinicians worldwide to advance research and improve diagnosis, care and quality of life.
1 in 30,000
Prevalence
6
Identified genes
~75% of cases
Associated with CNGA3 and CNGB3
How Achromatopsia can affect vision
Reduced or absent colour vision
People with achromatopsia may see the world mainly in shades of grey or have severely reduced ability to distinguish colours.
Light sensitivity (photophobia)
Extreme sensitivity to bright light is one of the most common features of achromatopsia.
Bright environments may cause discomfort and make it difficult to see clearly.
Reduced visual acuity
Many people have reduced sharpness of vision, particularly in bright conditions.
Nystagmus
Some individuals experience involuntary eye movements, especially during infancy.
Difficulty seeing in bright environments
Vision may improve in dim lighting because rod cells remain functional.
Reduced ability to see fine details
Reading, recognising faces, and tasks requiring detailed vision may be challenging.
Symptoms and severity can vary depending on the genetic cause and level of cone function remaining.
Identifying Achromatopsia
Eye examination
An ophthalmologist evaluates visual function and examines the retina.
Visual acuity testing
This measures the clarity of vision and helps assess the impact of reduced cone function.
Colour vision testing
Specialised tests assess the ability to perceive and distinguish colours.
Electroretino-graphy (ERG)
An ERG evaluates retinal function by measuring electrical responses from photoreceptor cells.
In achromatopsia, cone responses are typically reduced or absent.
Optical coherence tomography (OCT)
OCT imaging provides detailed images of retinal layers and may identify changes in cone-related areas.
Genetic testing
Genetic testing can identify the gene responsible for achromatopsia and confirm diagnosis.
A genetic diagnosis can support:
- Understanding inheritance
- Accessing clinical research
- Future treatment planning
- Family decisions
Current approaches to managing Achromatopsia
Managing light sensitivity
Approaches may include:
- Tinted lenses
- Specialised sunglasses
- Adaptive lighting environments
- Glare reduction strategies
Low vision support
Specialist services can provide:
- Magnification tools
- Assistive technology
- Digital accessibility tools
- Reading support
Educational and workplace support
Children and adults may benefit from:
- Classroom adaptations
- Accessible materials
- Workplace adjustments
- Assistive devices
Vision rehabilitation
Rehabilitation can support:
- Independent living
- Mobility
- Confidence in daily activities
Emerging treatments
Although there is currently no cure, promising research is investigating gene therapy, CRISPR gene editing, and stem-cell technology. Gene therapy targeting the CNGA3 and CNGB3 genes is the most advanced approach, with human clinical trials reporting modest improvements in some aspects of visual function. CRISPR aims to correct the underlying genetic mutations, while stem-cell research explores the possibility of replacing damaged cone cells; both remain experimental. Current management focuses on reducing light sensitivity, improving functional vision and providing regular specialist eye care. Overall, international research offers hope for future treatments, but further clinical trials are needed to establish their safety and effectiveness.
Adapting to life with reduced colour vision and light sensitivity
Achromatopsia can affect how people see and interact with the world, but with the right support and adaptations, many people take part fully in education, work, relationships, and daily life.
Support may include:
- Low vision services
- Assistive technology
- Accessible environments
- Patient organisations and peer support
Common challenges can include bright environments, reading standard print, recognising visual information, and accessing information that relies on colour.
Understanding and appropriate support from schools, workplaces, and communities can help people with achromatopsia live independently. The experiences of people living with the condition are also important in shaping better care, accessibility, and research.
Useful External Resources
Advancing the future of Achromatopsia treatment
Gene therapy
Researchers are investigating whether delivering functional copies of affected genes can restore cone cell activity.
Gene therapy approaches have focused particularly on:
- CNGA3-associated achromatopsia
- CNGB3-associated achromatopsia
Retinal cell therapies
Retinal cell therapies explore the replacement or regeneration of damaged retinal cells to help restore visual function.
Retinal prostheses and vision restoration technologies
Retinal prostheses and vision restoration technologies use innovative devices and technologies to stimulate remaining retinal pathways and support vision.
Natural history studies and registries
Natural history studies and registries collect long-term data to better understand how disease progresses and to guide future treatment development.
Clinical trials
Clinical trials evaluate the safety and effectiveness of new therapies, medicines, and technologies for people living with this disease.
Information and community support
Take the Next Step
Achromatopsia demonstrates the importance of understanding genetic causes of retinal conditions and developing targeted approaches that address specific changes affecting vision.
Through collaboration between patients, researchers, clinicians, and organisations worldwide, progress continues towards improved support, innovative therapies, and a future where people affected by inherited retinal diseases have more opportunities to preserve and restore vision.
-
close